- incredible headlines coming out of Pfizer
- RSV vaccine announcement is huge
- EPS forecast: $1.39; actual, $1.78;
From the linked article:
On average, analysts polled by FactSet expected Pfizer (PFE) to earn $1.39 per share on $21.07 billion in sales.
In the year-earlier period, Pfizer earnings were $1.27 per share and the company reported $24.04 billion in sales.
Pfizer raised its guidance for 2022 and now projects adjusted profit of $6.40 to $6.50 per share and $99.5 billion to $102 billion in sales. Pfizer stock analysts polled by FactSet expected adjusted profit of $6.40 per share and $99.66 billion in sales.
Pfizer also announced promising results for its respiratory syncytial virus vaccine in pregnant women. The vaccine proved 81.8% effective in preventing the respiratory illness called RSV in the first 90 days of an infant's life when administered to the mother during pregnancy. It was 69.4% effective during the first six months of life. The news comes amid a recent surge in RSV cases.
No comments:
Post a Comment